US · DRTS
Alpha Tau Medical Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Jerusalem 9777605
- Website
- alphatau.com
Price · as of 2024-12-31
$8.54
Market cap 661.65M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $9.79 | ||||
| 2021 | $11.80 | ||||
| 2022 | $3.25 | ||||
| 2023 | $3.01 | ||||
| 2024 | $2.77 |
AI valuation
Our deep-learning model estimates Alpha Tau Medical Ltd.'s (DRTS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $8.54
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DRTS | Alpha Tau Medical Ltd. | $8.54 | 661.65M | — | — | — | — | -6.09 | 3.09 | — | -4.83 | -85.26 | 3.09 | 0.00% | — | — | -43.16% | -228.37% | -32.80% | 0.20 | -104.77 | 7.40 | 6.91 | 0.04 | 714.00% | — | -960.00% | -11.39% | -2.28 | -139.53% | 0.00% | 0.00% | 0.93% | -4.06 | -6.64 | — | 1.93 |
| ACIU | AC Immune S.A. | $2.93 | 294.76M | +1,817% | -50% | — | — | -3.77 | 1.71 | 7.03 | -0.66 | — | 3.10 | -129.12% | -191.80% | -186.44% | -37.31% | -787.64% | -24.61% | 0.05 | -393.82 | 1.71 | 1.65 | 0.63 | -2031.00% | 8451.00% | -20663.00% | 34.00% | 0.65 | 981.44% | 0.00% | 0.00% | 0.00% | -0.61 | 0.49 | 1.17 | -1.52 |
| ALDX | Aldeyra Therapeutics, Inc… | $5.46 | 328.49M | — | — | — | — | 0.00 | 0.00 | — | 1.55 | — | 0.00 | 0.00% | — | — | -152.98% | 0.00% | -93.94% | 0.35 | -18.51 | 2.58 | 2.52 | 1.55 | -4043.00% | — | 7717335287.00% | -9879606.86% | -1.20 | 649.97% | 0.00% | 0.00% | 16150447.97% | 1545737.39 | 1.63 | — | -8.67 |
| AMRN | Amarin Corporation plc | $13.80 | 285.42M | +2,553% | -43% | -73% | +374% | -2.65 | 0.45 | 0.95 | 0.93 | -7.95 | 0.46 | 35.60% | -40.15% | -35.95% | -15.83% | -41.74% | -10.83% | 0.02 | -13113.86 | 3.31 | 2.31 | 1.53 | 3333.00% | -2551.00% | -55089.00% | -14.25% | -0.17 | -14.11% | 0.00% | 0.00% | 0.00% | 0.75 | 2.21 | -0.30 | -2.13 |
| ANRO | Alto Neuroscience, Inc. | $19.69 | 611.7M | — | — | — | — | -1.42 | 0.58 | — | 0.93 | -1.67 | 0.58 | 0.00% | — | — | -153.99% | 95.25% | -46.51% | 0.11 | 49.90 | 16.92 | 16.81 | 2.20 | 8519.00% | — | 4594.00% | -56.68% | -4.74 | 68.72% | 0.00% | 0.00% | 90.14% | 0.93 | 1.29 | — | 0.72 |
| CADL | Candel Therapeutics, Inc. | $5.25 | 288.22M | — | — | — | — | -4.74 | 3.94 | — | -3.31 | -14.45 | 3.94 | 0.00% | — | — | -139.56% | 293.22% | -74.53% | 0.20 | -15.97 | 2.77 | 2.74 | 1.71 | 3282.00% | — | -2208.00% | -10.33% | -0.72 | 237.58% | 0.00% | 0.00% | 29.25% | -5.17 | -6.38 | — | 1.07 |
| CLLS | Cellectis S.A. | $3.88 | 389.18M | +21,055% | +605% | — | — | -3.10 | 0.87 | 2.74 | 5.83 | — | 0.87 | 77.88% | -143.48% | -88.57% | -34.02% | 165.71% | -10.22% | 0.70 | -7.99 | 1.73 | 1.70 | 5.47 | -7684.00% | 539748.00% | -17562.00% | 17.18% | 0.13 | -54.33% | 0.00% | 0.00% | 0.12% | 0.93 | -2.83 | -1.33 | -0.96 |
| DBVT | DBV Technologies S.A. | $20.99 | 502.12M | -17% | — | — | — | -0.71 | 2.93 | — | -0.50 | -1.28 | 2.94 | 0.00% | — | — | -135.96% | -2872.45% | -91.63% | 0.28 | — | 1.43 | 1.38 | 0.22 | 5526.00% | -10000.00% | 3297.00% | -132.98% | -3.36 | -2637.08% | 0.00% | 0.00% | 0.06% | -0.46 | -0.52 | — | -10.66 |
| DMAC | DiaMedica Therapeutics In… | $7.95 | 414.02M | — | — | — | — | -9.54 | 5.73 | — | -7.11 | — | 5.73 | 0.00% | — | — | -53.27% | 1178.75% | -48.64% | 0.01 | — | 8.28 | 8.23 | 0.10 | 0.00% | — | 1786.00% | -9.48% | -4.10 | 976.41% | 0.00% | 0.00% | 0.00% | -7.10 | -8.57 | — | 19.75 |
| GNLX | Genelux Corporation | $2.98 | 112.1M | +972% | — | — | +2,543% | -4.42 | 5.03 | 16511.63 | -3.56 | — | 5.03 | -11187.50% | -396200.00% | -373362.50% | -130.58% | 1604.05% | -95.41% | 0.07 | — | 4.57 | 4.48 | 0.23 | -1810.00% | -9529.00% | 145.00% | -16.36% | -3.08 | 1093.57% | 0.00% | 0.00% | 0.00% | -3.25 | -4.77 | 12883.26 | -2.91 |
| LRMR | Larimar Therapeutics, Inc… | $5.31 | 454.48M | — | — | — | — | -2.30 | 1.08 | — | -0.08 | -4.03 | 1.08 | 0.00% | — | — | -63.58% | 3005.12% | -54.43% | 0.03 | — | 8.02 | 7.58 | 0.31 | 5714.00% | — | 11198.00% | -38.40% | -2.91 | 2356.59% | 0.00% | 0.00% | 3.72% | -0.08 | -0.10 | — | 1.56 |
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
- CEO
- Uzi Sofer
- Employees
- 125
- Beta
- 1.05
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $8.54) − 1 = — (DCF, example).